Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16106143 | 0.88 | MEN1 (0.73) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4681925 | 0.88 | MEN1 (0.86) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL29269293 | 0.85 | MEN1 (0.67) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3923314 | 0.85 | MEN1 (0.89) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL11518363 | 0.84 | MEN1 (0.81) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL11652739 | 0.84 | MEN1 (0.86) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL16289643 | 0.83 | MEN1 (0.79) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL29269298 | 0.83 | MEN1 (0.79) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL29269467 | 0.83 | MEN1 (0.79) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12335729 | 0.81 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799822-B2 | Phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | MEN1 2498/4885KMT2A 2855/4885SMN1; SMN2 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.